Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1116 | 1116 | 1183 | 1427 | 1725 | 2499 |
Fund Return | 11.56% | 11.56% | 18.28% | 12.59% | 11.52% | 9.59% |
Place in category | 988 | 988 | 546 | 704 | 318 | 310 |
% in Category | 46 | 46 | 26 | 41 | 20 | 32 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Handelsbanken Sverige Index A1 SEK | 66.29B | 7.07 | 5.30 | 10.26 | ||
Handelsbanken Sverige Index B1 SEK | 66.29B | 7.08 | 5.30 | 9.79 | ||
Handelsbanken MSCI USA Index utd | 57.17B | 17.03 | 17.79 | 17.89 | ||
Handelsbanken MSCI USA Index | 53.21B | 16.34 | 16.70 | 18.25 | ||
Handelsbanken European Index utd | 20.24B | 11.56 | 12.59 | 9.11 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Handelsbanken European Index utd | 20.24B | 11.56 | 12.59 | 9.11 | ||
SPP Aktiefond Europa | 17.07B | 12.19 | 12.76 | 9.46 | ||
Swedbank Robur Access Europa | 13.41B | 15.69 | 15.26 | 9.92 | ||
FI4000048988 | 10.78B | 11.71 | 11.06 | 9.95 | ||
Lansforsakringar Europa Indexnara | 10.6B | 12.29 | 12.48 | 9.29 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 4.36 | 883.2 | +0.07% | |
ASML Holding | NL0010273215 | 4.17 | 864.50 | +1.96% | |
Nestle | CH0038863350 | 3.01 | 95.18 | +1.04% | |
AstraZeneca | GB0009895292 | 2.29 | 12,370.0 | +0.31% | |
Novartis | CH0012005267 | 2.24 | 92.32 | +1.97% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review